Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 12 04:00PM ET
0.3421
Dollar change
-0.0089
Percentage change
-2.54
%
Index- P/E- EPS (ttm)-1.23 Insider Own6.94% Shs Outstand100.77M Perf Week-15.59%
Market Cap34.47M Forward P/E- EPS next Y-0.41 Insider Trans0.32% Shs Float93.78M Perf Month-11.51%
Income-121.79M PEG- EPS next Q-0.22 Inst Own45.77% Short Float3.66% Perf Quarter-27.21%
Sales180.01M P/S0.19 EPS this Y69.86% Inst Trans-21.61% Short Ratio2.93 Perf Half Y-70.51%
Book/sh-2.42 P/B- EPS next Y53.41% ROA-33.61% Short Interest3.44M Perf Year-44.82%
Cash/sh1.30 P/C0.26 EPS next 5Y- ROE- 52W Range0.18 - 2.93 Perf YTD-61.40%
Dividend Est.- P/FCF- EPS past 5Y-23.23% ROI- 52W High-88.32% Beta0.83
Dividend TTM- Quick Ratio1.16 Sales past 5Y-2.51% Gross Margin76.87% 52W Low90.06% ATR (14)0.04
Dividend Ex-Date- Current Ratio1.28 EPS Y/Y TTM59.81% Oper. Margin-52.44% RSI (14)43.58 Volatility12.07% 15.62%
Employees486 Debt/Eq- Sales Y/Y TTM16.15% Profit Margin-67.66% Recom4.00 Target Price1.50
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q73.75% Payout- Rel Volume0.40 Prev Close0.35
Sales Surprise32.98% EPS Surprise44.50% Sales Q/Q15.45% EarningsNov 12 AMC Avg Volume1.17M Price0.34
SMA20-9.03% SMA50-3.32% SMA200-61.90% Trades Volume472,649 Change-2.54%
Date Action Analyst Rating Change Price Target Change
Aug-08-23Downgrade BofA Securities Neutral → Underperform $4 → $2
Jun-26-23Downgrade William Blair Outperform → Mkt Perform
Jun-26-23Downgrade Stifel Buy → Hold
Jun-26-23Downgrade Raymond James Outperform → Mkt Perform
Jun-26-23Downgrade BofA Securities Buy → Neutral
Jun-02-23Upgrade Stifel Hold → Buy $23 → $32
Jan-31-23Upgrade William Blair Mkt Perform → Outperform
Jan-26-23Upgrade Raymond James Mkt Perform → Outperform $35
Jan-05-23Upgrade BofA Securities Neutral → Buy $18 → $27
Sep-22-21Downgrade Goldman Neutral → Sell $16 → $11
Nov-13-24 10:22AM
02:21AM
Nov-12-24 06:10PM
05:06PM
04:05PM
04:05PM Loading…
Nov-04-24 04:05PM
Oct-09-24 05:09PM
Sep-16-24 01:32AM
Sep-03-24 04:05PM
Aug-06-24 06:15PM
05:10PM
04:05PM
Jul-31-24 11:54AM
07:33AM
Jul-30-24 04:07PM
04:05PM Loading…
04:05PM
Jun-18-24 08:00AM
Jun-12-24 10:22AM
Jun-04-24 07:28AM
Jun-03-24 04:05PM
04:02PM
09:17AM
07:00AM
May-28-24 06:10AM
May-23-24 05:05PM
May-07-24 10:15AM
08:57AM
07:39AM
07:36AM
07:00AM
03:14AM Loading…
03:14AM
May-06-24 08:58PM
04:25PM
04:02PM
Apr-29-24 07:00AM
Apr-24-24 04:02PM
Apr-03-24 09:32AM
Apr-02-24 05:46PM
Mar-26-24 07:00AM
Mar-20-24 03:45PM
Mar-11-24 07:00AM
Feb-29-24 08:09AM
Feb-27-24 09:59AM
Feb-26-24 05:50PM
04:40PM
04:34PM
04:15PM
04:06PM
04:05PM
Feb-20-24 07:00AM
Feb-05-24 07:00AM
Jan-25-24 07:00AM
Dec-09-23 05:02PM
Nov-07-23 11:01AM
10:01AM
Nov-06-23 05:33PM
05:30PM
04:10PM
04:01PM
Oct-23-23 07:00AM
Aug-31-23 10:15AM
Aug-30-23 11:09AM
Aug-29-23 06:00PM
04:15PM
Aug-16-23 09:35AM
Aug-09-23 09:14AM
Aug-08-23 10:08AM
08:59AM
Aug-07-23 07:30PM
05:40PM
04:26PM
04:01PM
Jul-31-23 09:00AM
Jul-25-23 10:49AM
07:00AM
Jul-24-23 07:00AM
Jul-21-23 07:17AM
Jul-19-23 10:50AM
Jul-14-23 09:55AM
Jul-11-23 09:35AM
Jul-01-23 08:46AM
Jun-27-23 12:45PM
Jun-26-23 04:04PM
11:34AM
07:22AM
07:11AM
07:04AM
Jun-08-23 01:03PM
Jun-07-23 04:03PM
11:47AM
07:02AM
06:55AM
Jun-06-23 04:01PM
02:06PM
May-18-23 07:30AM
May-09-23 10:22AM
May-08-23 05:15PM
04:12PM
04:01PM
04:00PM
FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Adib DeyaaChief Medical OfficerJun 12 '24Buy1.1722,12325,88482,123Jun 13 04:30 PM
Wettig ThaneCEOMar 07 '24Buy1.9150,00095,470470,178Mar 11 07:06 PM